OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 116 filers reported holding OCULAR THERAPEUTIX INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,247 | -39.1% | 397 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $2,049 | -2.1% | 397 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,092 | +87.5% | 397 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $1,116 | -44.2% | 397 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $2,000 | -33.3% | 397 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $3,000 | -25.0% | 397 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $4,000 | -33.3% | 397 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $6,000 | -14.3% | 397 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $7,000 | -12.5% | 397 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $8,000 | -55.6% | 397 | -83.4% | 0.01% | -56.2% |
| Q3 2020 | $18,000 | -10.0% | 2,397 | 0.0% | 0.02% | -27.3% |
| Q2 2020 | $20,000 | +81.8% | 2,397 | 0.0% | 0.02% | +69.2% |
| Q1 2020 | $11,000 | +22.2% | 2,397 | 0.0% | 0.01% | +30.0% |
| Q4 2019 | $9,000 | – | 2,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $19,223 | 100.00% |
| Opaleye Management Inc. | 6,468,000 | $20,309,520 | 6.61% |
| DELTEC ASSET MANAGEMENT LLC | 2,061,797 | $6,474,043 | 1.48% |
| Endurant Capital Management LP | 353,707 | $1,110,640 | 1.00% |
| SECTORAL ASSET MANAGEMENT INC | 969,350 | $3,043,759 | 0.59% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $609,995 | 0.09% |
| Covestor Ltd | 37,404 | $117 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 233,582 | $733 | 0.06% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 342,111 | $1,074,229 | 0.03% |
| Polar Asset Management Partners Inc. | 263,763 | $828,216 | 0.02% |